BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25620650)

  • 1. Rates of complete diagnostic testing for patients with acute myeloid leukemia.
    Lin TL; Williams T; He J; Aljitawi OS; Ganguly S; Abhyankar S; Fleming A; Male H; McGuirk JP
    Cancer Med; 2015 Apr; 4(4):519-22. PubMed ID: 25620650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
    He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].
    Ding ZX; Shen HJ; Miao JC; Chen SN; Qiu QC; Qi XF; Jin ZM; Wu DP; He J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):829-34. PubMed ID: 23384905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
    Kansal R
    Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosomal Abnormalities and Prognosis in
    Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
    J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system.
    Byrd JC; Gatz JL; Louis CL; Mims AS; Borate U; Yocum AO; Gana TJ; Burd A
    Cancer Med; 2023 Sep; 12(17):18368-18380. PubMed ID: 37635639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
    Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
    Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetically Normal Acute Myeloid Leukaemia at a Single Centre in South Africa.
    Jenkins N; Blanshard LA; Stone M; Verburgh E; Oosthuizen J; Shires K
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):397-406. PubMed ID: 37363984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.
    Herlin MK; Yones SA; Kjeldsen E; Holmfeldt L; Hasle H
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34064268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia.
    Wang S; Zhang YX; Huang T; Sui JN; Lu J; Chen XJ; Wang KK; Xi XD; Li JM; Huang JY; Chen B
    Int J Lab Hematol; 2018 Aug; 40(4):408-418. PubMed ID: 29573577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
    Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P;
    Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
    Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
    J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.
    Sloan CE; Luskin MR; Boccuti AM; Sehgal AR; Zhao J; Daber RD; Morrissette JJ; Luger SM; Bagg A; Gimotty PA; Carroll M
    PLoS One; 2016; 11(4):e0153016. PubMed ID: 27050425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
    Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
    Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.